ArticleOncology letters2017
A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target.Pharmacological reports : PR · 2026Review
- Immune cell infiltration and drug response in glioblastoma multiforme: insights from oxidative stress-related genes.Cancer cell international · 2024Article
- TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma.Acta neuropathologica communications · 2023Article
- Physiological and Pathophysiological Roles of Thioredoxin Interacting Protein: A Perspective on Redox Inflammation and Metabolism.Antioxidants & redox signaling · 2023Review
- Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.The American journal of pathology · 2022Article
- Txnip deficiency promotes β-cell proliferation in the HFD-induced obesity mouse model.Endocrine connections · 2022Article
- A novel necroptosis-related gene signature for predict prognosis of glioma based on single-cell and bulk RNA sequencing.Frontiers in molecular biosciences · 2022Article
- The Role of the Thioredoxin Detoxification System in Cancer Progression and Resistance.Frontiers in molecular biosciences · 2022Review
- Expression of TXNIP is associated with angiogenesis and postoperative relapse of conventional renal cell carcinoma.Scientific reports · 2021Article
- Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients.Nature communications · 2021Article
- Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.International journal of molecular sciences · 2020Review
- Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.Molecular neurobiology · 2020Article
- Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment.Antioxidants (Basel, Switzerland) · 2020Article
- Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress.Frontiers in molecular biosciences · 2020Review
- Redox RegulatorFrontiers in immunology · 2020Article
- Review
- Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells.Stem cells (Dayton, Ohio) · 2018Article
- Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.International journal of molecular sciences · 2018Article
- Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant glioma, the most common form of primary brain tumor, is associated with substantial morbidity and mortality, owing to the lack of response shown by patients to conventional therapies. Additional therapeutic targets and effective treatment options for these patients are therefore required. In the present study, a possible association of thioredoxin-interacting protein (TXNIP) with malignant glioma was evaluated. Initially, semi-quantitative and quantitative analysis of the expression levels of TXNIP in clinical specimens of primary glioma was performed via immunohistochemistry (IHC) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), respectively, and expression levels were further correlated to the overall survival time of the patients. The proliferative, migratory and invasive properties of the glioblastoma U251 cell line, engineered to downregulate TXNIP by lentiviral transfection of a specific short hairpin RNA, were evaluated by means of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.